Info

🌱 來自: Metastatic Colon Cancer

encorafenib

• Colorectal Cancer

• ORAL

• 300 mg once daily; use in combination with cetuximab. [ref] Continue therapy until disease progression or unacceptable toxicity occurs. [ref]

• If concomitant use with moderate or strong inhibitors of CYP3A4 cannot be avoided, reduce dosage of encorafenib.

• BEACON

  • Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-1643.